

A New Name, A New Era: Updates in MASLD/MASH

CPFI Annual Conference & National Student Retreat
Evan S Drake, PharmD, CPP
06 June 2026

Serving Christ and the World Through Pharmacy

1




Learning Objectives

- Describe the updated nomenclature and diagnostic criteria for MASLD and MASH.
- Apply current and emerging guidelines and clinical care pathways to identify and manage patients with MASLD/MASH in practice.
- Compare current and emerging pharmacologic therapies for MASLD/MASH based on efficacy, safety, and clinical role.
- Identify opportunities for pharmacist intervention to improve early detection and optimize management of MASLD/MASH.

Serving Christ and the World Through Pharmacy

2




Quick Poll


- Have you seen or used the terms MASLD or MASH prior to today?
- Have you utilized these terms in practice?

Serving Christ and the World Through Pharmacy

3




What We Learned...



Serving Christ and the World Through Pharmacy

4




Updated Nomenclature


OLD	NEW	Diagnostics: ≥5% hepatic steatosis
Non-alcoholic fatty liver disease (NAFLD)	Metabolic dysfunction-associated steatotic liver disease (MASLD)	>In the presence of at least 1 cardiometabolic risk factor >WITHOUT hepatocellular injury
Non-alcoholic steatohepatitis (NASH)	Metabolic dysfunction-associated steatohepatitis (MASH)	WITH hepatocellular injury and inflammation (± fibrosis)

Serving Christ and the World Through Pharmacy

5



Updated Algorithm



Serving Christ and the World Through Pharmacy

6

Why does this matter?

MASLD is the leading cause of chronic liver disease globally → 1 in 4 people

Less than 5% of persons with MASLD are aware of their liver disease

Moshir R, et al. Gastroenterol Res Pract. 2014;2014:209425.
Rizola ME, et al. Hepatology. 2012; 77:1879-1885.

Serving Christ and the World Through Pharmacy

7

Why does this matter?

COMMON UNDERDIAGNOSED PROGRESSIVE ACTIONABLE

Serving Christ and the World Through Pharmacy

8

Introducing...

CD

Past Medical History	Hypertension Type 2 Diabetes Overweight (BMI: 33 kg/m ²)
Social History	Works full-time as an insurance agent 1-2 beers/week Non-smoker
Pertinent Labs	AST: 38 ALT: 52 Platelets: 230
Imaging	Recent ultrasound shows hepatic steatosis (>5%)

Serving Christ and the World Through Pharmacy

9

CD

Which is the most appropriate classification for this patient?

a) Alcohol-associated liver disease
b) MASLD
c) MASH
d) Viral hepatitis

Serving Christ and the World Through Pharmacy

10

CD

Which is the most appropriate classification for this patient?

a) Alcohol-associated liver disease
b) MASLD
c) MASH
d) Viral hepatitis


Serving Christ and the World Through Pharmacy

11

Screening & Risk Stratification

Serving Christ and the World Through Pharmacy


12




13




14




15




16



17



18



19

CD

Past Medical History

- Hypertension
- Type 2 Diabetes
- Overweight (BMI: 33 kg/m²)

Social History

- Works full-time as an insurance agent
- 1-2 beers/week
- Non-smoker

Pertinent Labs

- AST: 38
- ALT: 52
- Platelets: 230

Imaging

- Recent ultrasound shows hepatic steatosis (>5%)

Serving Christ and the World Through Pharmacy

20

CD

With MASLD identified, what is the most appropriate next step in the work up of CD?

- a) Calculate FIB-4 score
- b) Order liver biopsy
- c) Start pharmacologic therapy
- d) Refer to hepatology

Serving Christ and the World Through Pharmacy

21

CD

With MASLD identified, what is the most appropriate next step in the work up of CD?

- a) Calculate FIB-4 score
- b) Order liver biopsy
- c) Start pharmacologic therapy
- d) Refer to hepatology

Serving Christ and the World Through Pharmacy

22

Management

Serving Christ and the World Through Pharmacy

23


Management – Broad Overview

	Low risk FIB-4 < 1.3 or VCTE LSM < 8 kPa or ELF < 8.2 or MRE LSM < 3.1 or Liver biopsy F0-F1	High risk VCTE LSM ≥ 8 kPa or ELF ≥ 8.2 or MRE LSM ≥ 3.1 or Liver biopsy F2+
Lifestyle intervention, including cessation of alcohol use ^a	Yes	Yes
Structured weight loss programs and/or antiobesity medications ^a	Yes, target of at least a 5%	Yes, target of at least a 10%
Bariatric surgery if indicated	Yes	Yes, can be considered in compensated cirrhosis, but contraindicated in decompensated cirrhosis ^a
Control of CVD risk factors (LDL-C, BP, A1C, etc.)	Yes	Yes
Statins are safe if indicated	Yes	Yes, except in decompensated cirrhosis ^a . Adjust dose if patient is on restraints ^a


Kamran F, et al. Gastroenterology. 2024;157(4):1065-1079. ©

Serving Christ and the World Through Pharmacy


24




25



26



27



28

CD a few years later

Past Medical History	Hypertension Type 2 Diabetes Overweight (BMI: 34 kg/m ²)
Social History	Works full-time as an insurance agent 1-2 beers/week Non-smoker
Pertinent Labs	AST: 52 Platelets: 165 ALT: 58
FIB-4	2.0
Follow	Referral to specialist. VCTE = 10.2 kPa

Kamal F, et al. Gastroenterology. 2025;159(10):2019-30
 DOI:10.1053/j.gastro.2025.05.001

29

CD a few years later

CD was referred to hepatology where a transient elastography is completed and results suggest moderate fibrosis. A follow up liver biopsy confirms MASH with F2 fibrosis. Patient states they are working on their diet and exercise, but asks can anything else be done? Which is the most appropriate next step?

- No pharmacologic therapy indicated
- Start pioglitazone
- Initiate GLP-1 RA
- Stop statin therapy

Kamal F, et al. Gastroenterology. 2025;159(10):2019-30
 DOI:10.1053/j.gastro.2025.05.001

30

CD a few years later

CD was referred to hepatology where a transient elastography is completed and results suggest moderate fibrosis. A follow up liver biopsy confirms MASH with F2 fibrosis. Patient states they are working on their diet and exercise, but asks can anything else be done? Which is the most appropriate next step?

- a) No pharmacologic therapy indicated
- b) Start pioglitazone
- c) Initiate GLP-1 RA
- d) Stop statin therapy

Serving Christ and the World Through Pharmacy

31

Medication Therapies

Serving Christ and the World Through Pharmacy

32

Management: Low-Risk

- Progression of liver disease is still a concern
- Management of cardiometabolic risk factors is a priority
- Weight-directed therapy
 - Semaglutide (Wegovy®) or tirzepatide (Zepbound®)
- Diabetes-directed therapy
 - Semaglutide (Ozempic®) or tirzepatide (Mounjaro®) or pioglitazone

Serving Christ and the World Through Pharmacy

33

Tirzepatide (Mounjaro®, Wegovy®)

Weight	↓↓↓
Glycemia	↓↓↓
LDL-C	↓
Liver steatosis	+ (phase 2)
Liver fibrosis	+ (phase 2)
CV outcomes	+ (phase 3) ¹
CKD outcomes	Not studied ²
OSA severity	+ (phase 3)
HFpEF severity	+ (phase 3)
Other cardiometabolic considerations	↓ TG; ↑ HDL-C; ↓ Blood pressure Rapid weight loss can lead to sarcopenia

Serving Christ and the World Through Pharmacy

34

Tirzepatide

SYNERGY-NASH				
Trial design	Phase 2, double-blind, randomized, placebo-controlled			
Dosing	5 mg, 10 mg, 15 mg			
Inclusion Criteria	Adults with biopsy-confirmed MASH with stage F2 or F3 fibrosis			
Primary End Point	Resolution of MASH without worsening of fibrosis at 52 weeks			
Secondary End Point	Improvement of at least one fibrosis stage without worsening of MASH			
Results – Primary	Placebo: 9.8%	5 mg: 43.6%	10 mg: 55.5%	15 mg: 62.4%
Results – Secondary	Placebo: 29.7%	5 mg: 54.9%	10 mg: 51.3%	15 mg: 51.0%
Conclusion	Tirzepatide is more effective than placebo			

Serving Christ and the World Through Pharmacy

35

Pioglitazone

Weight	↑
Glycemia	↓
LDL-C	↔
Liver steatosis	+ (phase 3)
Liver fibrosis	↔
CV outcomes	+ (phase 3)
CKD outcomes	Not studied ²
OSA severity	Not studied
HFpEF severity	-
Other cardiometabolic considerations	↓ TG; ↑ HDL-C Increases risk of bone fractures and anemia Change in fat distribution favorable

Serving Christ and the World Through Pharmacy

36

Pioglitazone

- Has shown improvement in steatohepatitis in patients with and without Type 2 Diabetes and MASH
- Several risks associated that should always be considered prior to therapy initiation

Bellotti R, et al. N Engl J Med. 2009;360(22):2307-2317.
Coker R, et al. Ann Intern Med. 2011;155(10):695-703.
Sanyal AJ, et al. N Engl J Med. 2010;362(18):1675-1685.

Serving Christ and the World Through Pharmacy

37

Management: High-Risk

- **Prevention of further progression and MASH resolution**
- Resmetirom (Rezdiffra®)
- Semaglutide (Wegovy®)

Serving Christ and the World Through Pharmacy

38

Resmetirom (Rezdiffra®)

EFFECTS		
Weight		↔
Glycemia		↔
LDL-C		↓↓
Liver steatosis		+ (phase 3)
Liver fibrosis		+ (phase 3)
CV outcomes		Not studied
CKD outcomes		Not studied
OSA severity		Not studied
HFpEF severity		Not studied
Other cardiometabolic considerations		↓ TG; ↓ Lp(a); ↑ SHBG with consequent increase in total testosterone and estradiol levels ^a

Kovachik P, et al. Gastroenterology. 2020;158(5):1055-1067.

Serving Christ and the World Through Pharmacy

39

Resmetirom (Rezdiffra®)

Indication	Noncirrhotic metabolic dysfunction-associated steatotic liver disease with moderate to advanced liver fibrosis (F2 or F3)	
Mechanism of Action	Thyroid Hormone Receptor-Beta (THR-β) Agonist	
Dosing	< 100 kg = 80 mg once daily	≥ 100 kg = 100 mg once daily
Warnings/Precautions	Hepatotoxicity	Gallbladder-related
Adverse Reactions	Diarrhea, nausea, pruritic, vomiting, constipation, abdominal pain Transient increase in ALT/AST	
Drug-Drug Interactions	CYP2C8 inhibitors	Select statins

Rezdiffra (Resmetirom) [Package Insert], 2024
Harrison CA, et al. N Engl J Med. 2024;390(12):1095-1105.

Serving Christ and the World Through Pharmacy

40

MAESTRO-NASH Trial

A NASH Resolution with No Worsening of Fibrosis

Group	Percentage of Patients
Placebo (N=318)	9.7
Resmetirom, 80 mg (N=316)	25.9
Resmetirom, 100 mg (N=321)	29.9

B Fibrosis Improvement by ≥1 Stage with No Worsening of NAFLD Activity Score

Group	Percentage of Patients
Placebo (N=318)	14.2
Resmetirom, 80 mg (N=316)	24.2
Resmetirom, 100 mg (N=321)	25.9

Harrison CA, et al. N Engl J Med. 2024;390(12):1095-1105.

Serving Christ and the World Through Pharmacy

41

Semaglutide (Wegovy®)

EFFECTS		
Weight		↓↓↓
Glycemia		↓↓↓
LDL-C		↓
Liver steatosis		+ (phase 3)
Liver fibrosis		+ (phase 3)
CV outcomes		+ (phase 3)
CKD outcomes		+ (phase 3)
OSA severity		Not studied ^a
HFpEF severity		+ (phase 3)
Other cardiometabolic considerations		↓ TG; ↑ HDL-C; ↓ Blood pressure Rapid weight loss can lead to sarcopenia

Kovachik P, et al. Gastroenterology. 2020;158(5):1055-1067.

Serving Christ and the World Through Pharmacy

42

Semaglutide (Wegovy®)

Indication	Noncirrhotic metabolic dysfunction-associated steatotic liver disease with moderate to advanced liver fibrosis (F2 or F3)
Mechanism of Action	GLP-1 receptor agonist
Dosing	Target maintenance dosage: 2.4 mg once weekly
Warnings/Precautions	Consistent with other Wegovy-treated conditions
Adverse Reactions	Consistent with other Wegovy-treated conditions

Serving Christ and the World Through Pharmacy

43

ESSENCE Trial

A Resolution of Steatohepatitis with No Worsening of Liver Fibrosis
 Estimated difference, 28.7 (95% CI, 21.1–36.2)
 P<0.001

Treatment	Percentage of Patients
Semaglutide, 2.4 mg (N=534)	62.9
Placebo (N=266)	34.3

B Reduction in Liver Fibrosis with No Worsening of Steatohepatitis
 Estimated difference, 14.4 (95% CI, 7.5–21.3)
 P<0.001

Treatment	Percentage of Patients
Semaglutide, 2.4 mg (N=534)	16.8
Placebo (N=266)	22.4

Figure 1. Primary End Points.

Serving Christ and the World Through Pharmacy

44

In the works...

- Semaglutide: ESSENCE Part 2
 - Long-term clinical outcomes for prevention of major adverse liver outcomes (MALO)
 - MASH and moderate-to-advanced liver fibrosis (F2/F3)
- Resmetrom: MAESTRO-NASH-OUTCOMES
 - Compensated cirrhosis
 - MALO
- Tirzepatide: SYNERGY-OUTCOMES
 - Tirzepatide & retatrutide
 - MASLD
 - Prevention of MALO

Serving Christ and the World Through Pharmacy

45

Opportunities for Pharmacists

Serving Christ and the World Through Pharmacy

46

The Problem

What We Have	What Often Happens
Patients seen regularly FIB-4 pathways	Never Calculated
Noninvasive Staging	Delayed referral
Effective Therapies	Late identification

Serving Christ and the World Through Pharmacy

47

A Solution

Serving Christ and the World Through Pharmacy

48

Opportunity #1: Identification

Recognize and Act

Serving Christ and the World Through Pharmacy

49

Opportunity #2: FIB-4 Implementation

```

graph TD
    A[Labs Available] --> B[Calculate FIB-4]
    B --> C[Risk Stratification]
    C --> D[Escalate As Need]
  
```

Serving Christ and the World Through Pharmacy

50

Opportunity #3:
Cardiometabolic Optimization

Diabetes	Cardiovascular Risk	Weight Management
GLP-1 Receptor Agonists	Statin therapy	Nutrition
Pioglitazone	Blood pressure control	Physical Activity
SGLT-2 inhibitors		Anti-obesity medication therapies

Serving Christ and the World Through Pharmacy

51

Opportunity #4: System-Level

- EHR-based FIB-4 calculators
- Automatic fibrosis risk alerts
- Collaborative practice agreements
- Referral protocols
- Population health screening

Serving Christ and the World Through Pharmacy

52

Pharmacist Take-Away

Which of the following represents an opportunity for pharmacists to be impactful in the identification and optimization of MASLD/MASH management?

- Implement FIB-4 screening protocols within the clinic.
- Optimize cardiometabolic risk factors, including diabetes, weight management, and cardiovascular disease management
- Provide patient education on lifestyle modifications and adherence to pharmacologic therapy
- All of the above

Serving Christ and the World Through Pharmacy

53

Pharmacist Take-Away

Which of the following represents an opportunity for pharmacists to be impactful in the identification and optimization of MASLD/MASH management?

- Implement FIB-4 screening protocols within the clinic.
- Optimize cardiometabolic risk factors, including diabetes, weight management, and cardiovascular disease management
- Provide patient education on lifestyle modifications and adherence to pharmacologic therapy
- All of the above

Serving Christ and the World Through Pharmacy


54



Bringing it All Together

Serving Christ and the World Through Pharmacy

55



Bringing it All Together

Name	<ul style="list-style-type: none"> MASLD MASH
Identify	<ul style="list-style-type: none"> Recognize high risk patients
STAGE	<ul style="list-style-type: none"> FIB-4 Non-invasive imaging/blood work
ACT	<ul style="list-style-type: none"> Lifestyle Cardiometabolic optimization Pharmacotherapy when indicated

Serving Christ and the World Through Pharmacy

56



Bringing it All Together

You cannot treat what you do not identify

You can make a difference

Serving Christ and the World Through Pharmacy


57



Questions?

Serving Christ and the World Through Pharmacy

58




References

- Manikar R, Ahmed A, Kim D. Current epidemiology of chronic liver disease. *Gastroenterol Rep (Oxf)*. 2024 Jun 24;12:gsoe069. doi: 10.1093/gastro/gsoe069.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023; 77:1927-1955.
- Kanwal F, Biri F, et al. Clinical care pathway for the risk stratification and management of patients with metabolic dysfunction-associated steatotic liver disease. *Gastroenterology*. 2026;S0016-5085(26)00198-8. doi: 10.1053/j.gastro.2026.01.047.
- Loomis R, Hartman M, Lawitz EJ, et al. Tripartite for metabolic dysfunction-associated steatohepatitis with liver fibrosis. *N Engl J Med*. 2024;381(4):299-310. doi: 10.1056/NEJMoa2401943.
- Bellfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006;355:2297-2307.
- Cusi K, Orsak B, Biri F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. *Ann Intern Med* 2016;165:305-315.
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010;362:1675-1685.
- Rezdiffra (Resmetrom) [package insert]. West Conshohocken, PA: Madrigal Pharmaceuticals; 2024.
- Harrison SA, Bedossa F, Guy CD, et al. A phase 3, randomized, controlled trial of Resmetrom in NASH with liver fibrosis. *N Engl J Med* 2024;390:497-509.
- Wegovy (semaglutide) [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2026.
- Sanyal AJ, Newsome PN, Kozarski T, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med*. 2025;392:2089-2099. doi: 10.1056/NEJMoa2413258.

Serving Christ and the World Through Pharmacy

59



A New Name, A New Era: Updates in MASLD/MASH

CPFI Annual Conference & National Student Retreat
Evan S Drake, PharmD, CPP
06 June 2026

Serving Christ and the World Through Pharmacy

60